No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects

Maraviroc is a C‐C chemokine receptor type‐5 antagonist approved for the treatment of HIV‐1. Previous studies show that cytochrome P450 3A5 (CYP3A5) plays a role in maraviroc metabolism. CYP3A5 is subject to a genetic polymorphism. The presence of 2 functional alleles (CYP3A5*1/*1) confers the exten...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Pharmacol
Hlavní autoři: Vourvahis, Manoli, McFadyen, Lynn, Nepal, Sunil, Valluri, Srinivas Rao, Fang, Annie, Fate, Gwendolyn D., Wood, Linda S., Marshall, Jean‐Claude, Chan, Phylinda L. S., Nedderman, Angus, Haynes, Julian, Savage, Mark E., Clark, Andrew, Smith, Kimberly Y., Heera, Jayvant
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Pharmacogenomics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6586010/
https://ncbi.nlm.nih.gov/pubmed/30192390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1306
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky